Premium
Recombinant human interleukin 6 (B‐cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1)
Author(s) -
Miyaura Chisato,
Onozaki Kikuo,
Akiyama Yukio,
Taniyama Tadayoshi,
Hirano Toshio,
Kishimoto Tadamitsu,
Suda Tatsuo
Publication year - 1988
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(88)81293-6
Subject(s) - lymphokine , cellular differentiation , myeloid leukemia , interleukin 3 , leukemia , biology , myeloid , microbiology and biotechnology , cytokine , chemistry , cancer research , immunology , t cell , antigen presenting cell , biochemistry , antigen , immune system , gene
Recombinant human interleukin 6 (IL‐6), a lymphokine involved in the final differentiation of activated B‐cells into antibody‐forming cells, greatly suppressed proliferation and induced differentiation of murine myeloid leukemia cells (M1) into mature macrophage‐like cells. When M1 cells were treated with IL‐6, their growth was completely arrested as early as on day 2, and they were induced to differentiate morphologically into macrophage‐like cells. Differentiation‐associated properties such as phagocytic activity, adherence to the dish surface, Fc and C3 receptors, were also induced within 24 h by IL‐6, and they reached their respective maximal levels on day 2 or 3. The potency of IL‐6 in suppressing proliferation and inducing differentiation was much greater than that of 1α,25‐dihydroxyvitamin D 3 one of the most potent inducers of M1 cells. The present report indicates that IL‐6 is involved in the differentiation of not only B‐cells but also myeloid leukemia cells.